leadforensics

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

PHARMA REPORT

rss_Pharma.jpg...see all
Pharmaceutical Contract Manufacturing: World Industry and Market Outlook 2015-2025

Pharmaceutical Contract Manufacturing: World Industry and Market Outlook 2015-2025

Product code: PHA0028

  • Publication date: 11/02/2015
  • Number of Pages: 216
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

Contracted drug production – discover trends and segments with the highest revenue potential
Where is outsourced pharma manufacturing heading? Visiongain’s updated study predicts that industry’s revenues from 2015. We reveal the potential for sales growth. Also you can understand the trends, technologies for drugs, clients’ needs and opportunities.

Our new report provides you with revenue forecasts to 2025 at overall world market, submarket and national level. Avoid falling behind by missing critical data. Instead discover what’s happening now for those medical contracting services – outsourcing and off-shoring – hearing how you can gain.

Read on to explore the industry and discover what revenue its future market could generate.

Forecasts from 2015-2025 and other analysis show you commercial prospects 
From 2015, pharma contract manufacturing organisations (CMOs) hold great potential in medical materials, small-molecule drugs and biologicals. In this new report you will see how, where and why. 

Besides revenue forecasting to 2025, our new study shows you historical data, growth rates and market shares. You will see developments in technology and service offerings, finding their meaning. And also you will receive 77 tables, 57 charts and two research interviews with companies. 

You will hear what’s happening in the industry for contract manufacturing organisations (CMOs). You shall see, from 2015, where the needs and commercial opportunities exist. Discover the most lucrative pharmaceutical production services, including active compounds and complex agents.

There are gains through understanding those outsourcing services – find advantages for your work
Avoid struggles to find essential business data. Now you can stay ahead in knowledge for contracted drug making, benefiting your research, analysis and decisions. Finding information you need for producing medicines just got quicker and easier.

And the following sections explain how you can benefit from our new investigation.

Outsourced drug producing – forecasts from 2015 for the world market and submarkets
What are the secrets of the industry's progress? You will see the expected trends. Along with prediction of the overall world market for out-contracting drug production, our report shows you revenue forecasting of 11 submarkets to 2025 at world level:

•    Active pharmaceutical ingredients (APIs), with sub forecasts for generic APIs, high potency active pharma ingredients (HPAPIs) and other products
•    Finished dosage formulations (FDFs), with sub forecasts for solid dose forms, injectable dosages, and other agents
•    Other applications of outsourced production – other services
•    Clinical manufacturing
•    Commercial manufacturing.

You will see what’s possible. Our analyses and discussions illustrate to you the commercial potentials for manufacturing service providers and their technologies. Discover those money-making opportunities, finding how your company can prosper.

Use those predictions to expand your business and give you more influence. You will get the forecasting leaders need, benefiting your authority and helping you receive credit for your knowledge. Our study helps you stay ahead.

You will receive geographical revenue predictions, too, seeing where to find the best prospects. 

National and regional markets – what outlooks for demand, service provision and sales?
In developed and developing countries, opportunities for pharmaceutical CMOs will occur, often with rising potential. Our study reveals where and how.

Our analyses give individual revenue forecasts to 2025 for 12 national markets:

•    United States (US)
•    European Union – EU regional prediction
•    Germany, France, the UK, Italy and Spain – EU5 countries 
•    Brazil, Russia, India, China – BRIC nations
•    South Korea 
•    Japan.

There you can explore the progress and outlooks. And assess the medical production sector’s future – hear about developments and find their meaning.

That way you will gain a feel for the industry. Find opportunity and see what’s likely to happen. Our work explains, exploring the issues shaping the future.

Forces affecting pharma CMOs and clients
Our report shows you the activities, developments and events affecting the industry and market from 2015, including these:

•    Trends for investing in biopharma manufacturing
•    US and EU regulations, as well as requirements in other countries
•    Generic Drug User Fee Act and API producing 
•    Demand for formulation developing services 
•    GMP standards, quality by design (QbD) and virtual pharma companies
•    Potential for microreactors in outsourced drug making
•    Backwards integration for generics producers.

The analysis also discusses other influences, including these:

•    Investment in HPAPI manufacturing facilities
•    Complex-molecule production, esp. biologics (inc. biosimilars) and orphan medicines
•    Demand for softgel formulations and the shift to continuous manufacturing
•    Green technology in contract pharmaceuticals production
•    Aseptic filling for biological drugs and small-molecule medicines 
•    Development of antibody-drug conjugates (ADCs) and other novel proteins
•    Lyophilisation, spray drying, hot-melt extrusion and fill-finish services.

There you can explore the political, economic, social and technological questions, assessing the outlooks for business. You will be able to examine the forces stimulating and restraining the healthcare services industry.

You will also see the regulatory developments. Discover what that industry’s present and future hold exploring issues for contract drug makers and clients.

Companies and overall 2019 market value – how high can sales go?
What is possible for the industry? Our analysis predicts the world market for contract pharma manufacturing will reach $79.24bn in 2019. It will rise from $54.54bn in 2013, with strong revenue expansion to 2025. 

Our study also explains what service needs, technologies and outsourcing providers hold the greatest commercial potential. 

In particular, you can explore the activities, capabilities and results of these companies: 

•    Catalent Pharma Solutions
•    Lonza
•    Evonik Degussa
•    Royal DSM
•    Teva API.

You will also find discussions of these firms, among others:

•    Boehringer BioXcellence 
•    Vetter Pharma-Fertigung 
•    Patheon
•    Famar
•    Fareva.

There you can analyse participants’ financial results, market shares, activities and outlooks. Our study covers 150 organisations. You will also gain two interviews with authorities, including visiongain’s discussions with leaders in SAFC and Vetter Pharma International.

So discover what companies in the industry think, say and do, helping you to stay ahead.

Research and analysis on the CMO industry and market – data found nowhere else
Our new investigation helps you in these seven main ways:

•    Revenues to 2025 for outsourced medicine production at overall world level – explore the prospects for drug making technologies, investments, sales and contracts
•    Prospects of 11 submarkets – discover the revenue generating potentials of services custom pharma manufacturing organisations offer
•    Forecasts to 2025 for 12 national markets in the Americas, Europe and Asia – investigate developed and developing countries for those selling opportunities
•    Outlooks for established and rising CMOs – assess the portfolios, results, deals and outlooks, also with 10 company profiles
•    Needs of clients – explore the production requirements of drug companies, assessing the commercial opportunities in serving drug developers and marketers
•    Analysis of what stimulates and restrains the contract drug production market – see developments and challenges, helping you compete and gain advantage.
•    Interviews with companies and other news – discover what that industry’s participants think, say and do, helping you to stay ahead.

Our brand new report, by in-house UK-based analysts, benefits your reputation for knowledge, helping you succeed.

Analyses found nowhere else, helping your research, assessments and planning
Pharmaceutical Contract Manufacturing: World Industry and Market Outlook 2015-2025 provides independent analysis. You will receive business intelligence found only in our work. With our study you’re less likely to fall behind in essential market data or miss crucial opportunities.

You will find where the opportunities and most lucrative commercial prospects are. Gain also in recognition for insight. Our report’s purpose is to benefit your research, analysis and decisions, also saving you time and effort. 

Predictions for outsourced manufacture of pharmaceuticals – explore the industry’s future
Our new study is for everyone investigating production of small-molecule medicines and biological drugs. There you will find revenue forecasting to 2025, seeing trends, developments and industry opinion. Avoid missing out – instead please order this report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Table of Contents

1. Report Overview
1.1 Pharma Contract Manufacturing: World Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. Pharma Contract Manufacturing
2.1 An Introduction to Pharma Contract Manufacturing
2.1.1 Why Outsource in the Pharma Industry?
2.1.2 Services Offered by CMOs
2.1.3 Tactical and Strategic Manufacturing Outsourcing
2.1.4 Trends in Contract Manufacturing 2015-2025

3. The Pharma Contract Manufacturing Market: Outlook and Forecast 2015-2025
3.1 The Pharma Contract Manufacturing: Market Performance 2012-2013
3.1.1 Contract Manufacturing Is the Most Mature Pharma Outsourcing Sector
3.1.2 The Pharma Contract Manufacturing Market by Sector 2013
3.2 Pharma Contract Manufacturing: Overall Market Forecast 2015-2025
3.2.1 What Will Drive Growth for Contract Manufacturers 2015-2025?
3.2.2 Will Generics Drive or Restrain Market Growth?
3.2.3 Outlook and Revenue Forecast for Other Contract Manufacturing Services 2015-2025
3.2.3.1 Rising Demand for Formulation Development Services
3.3 Clinical and Commercial Manufacturing Services
3.3.1 Clinical-Stage Manufacturing: Submarket Forecast 2015-2025
3.3.2 Commercial-Stage Manufacturing: Submarket Forecast 2015-2025
3.4 Leading Contract Manufacturing Organisations (CMOs)
3.4.1 Catalent Pharma Solutions: The Market Leader
3.4.1.1 Expanding in Clinical and Biopharma Manufacturing
3.4.2 Lonza: An Expert in Biopharma Manufacturing
3.4.2.1 Lonza and Advanced Biopharma Manufacturing
3.4.3 Evonik Degussa: A Small Molecule Specialist
3.4.3.1 Growth in HPAPI Manufacturing
3.4.4 Royal DSM
3.4.4.1 Adding Biopharma Capacity
3.4.5 Teva API: The World’s Largest API Manufacturer
3.4.5.1 Will Teva Expand in Emerging Markets?
3.4.6 Patheon
3.4.6.1 Patheon Is Adding New Formulation Development Services
3.4.7 Boehringer BioXcellence: Boehringer’s Biopharma Manufacturing Division
3.4.7.1 Adding New Services for Growth
3.4.8 Famar
3.4.9 Fareva
3.4.10 Vetter Pharma: Aseptic Filling for Biologics and Small Molecules
3.4.10.1 Vetter Offers its Clients New Services

4. The Contract API Manufacturing Submarket: Outlook 2015-2025
4.1 The Contract API Manufacturing Submarket 2013
4.1.1 The API Manufacturing Submarket by Sector 2013
4.2 The Contract API Manufacturing Submarket Outlook 2014-2025
4.2.1 The Contract API Manufacturing Submarket Forecast 2015-2025
4.2.2 What Will Drive Submarket Growth to 2025?
4.2.2.1 The Potential for Microreactors in Commercial Manufacturing to 2025
4.2.3 How Will New EU Regulations Impact the API Manufacturing Submarket?
4.2.4 Contract API Manufacturing Submarket Restraints 2015-2025
4.2.4.1 Backwards Integration for Generics Manufacturers
4.3 The Contract Generic API Manufacturing Submarket 2015-2025
4.3.1 The Contract Generic API Manufacturing Submarket Forecast 2015-2025
4.3.2 The Contract Generic API Manufacturing Submarket Drivers and Restraints to 2025
4.3.2.1 The US Generic Drug User Fee Act and API Manufacturing
4.4 The Contract HPAPI Manufacturing Submarket 2015-2025
4.4.1 Challenges and Opportunities in High Containment Manufacturing
4.4.2 Many Companies Are Investing in HPAPI Manufacturing Facilities
4.4.3 The Contract HPAPI Manufacturing Submarket Forecast 2015-2025
4.4.4 Submarket Drivers and Restraints 2015-2025

5. The Contract FDF Manufacturing Submarket Outlook 2015-2025
5.1 The Contract FDF Manufacturing Submarket 2013
5.1.1 Solid Dosage Manufacturing Leads the Market
5.1.2 CMOs Report High Demand for Softgel Formulations
5.2 The Contract FDF Manufacturing Submarket Forecast 2015-2025
5.2.1 Complex Molecule Manufacturing Will Drive Growth to 2025
5.2.2 What Will Restrain Growth in FDF Outsourcing?
5.3 The Contract Solid Dosage Manufacturing Submarket 2015-2025
5.3.1 How Will Revenues for Solid Dosage Manufacturing Grow 2015-2025?
5.3.2 Submarket Drivers and Restraints 2015-2025
5.3.2.1 Will Product Reformulation Drive Growth to 2025?
5.4 The Contract Injectable Dosage Manufacturing Submarket 2015-2025
5.4.1 The Contract Injectable Dosage Manufacturing Submarket Forecast 2015-2025
5.4.1.1 Drug Shortages Offer an Opportunity for CMOs in the Short Term
5.4.2 Demand for Biopharma Manufacturing Will Drive Growth 2015-2025
5.4.2.1 Interest in Antibody Drug Conjugate Development Is Growing
5.4.2.2 Challenges in Manufacturing Antibody Drug Conjugates
5.4.3 Lyophilisation and Aseptic Filling Demand Will Rise
5.4.3.1 Will Spray Drying Replace Lyophilisation in FDF Manufacturing?

6. Pharma Contract Manufacturing: Leading Developed National Markets 2015-2025
6.1 Leading National Markets for Pharma Contract Manufacturing 2013
6.1.1 Challenges in Assessing the Market: Supply vs. Demand
6.1.2 Leading National Pharma Contract Manufacturing Markets: Revenue Forecasts 2015-2025
6.2 The US Is the Leading National Market in Terms of Demand
6.2.1 Pharma Manufacturing in the US: Regulatory Oversight 2013
6.2.1.1 Controlling Foreign Manufacturing Sites
6.2.1.2 What Impact Will the GDUFA 2012 Have on Foreign Manufacturing?
6.2.1.3 Outsourcing and US Manufacturing Regulations
6.2.2 Increased Demand for Domestic API Manufacturing?
6.2.3 The US Contract Manufacturing Submarket Forecast 2015-2025
6.3 Outlook for Pharma Contract Manufacturing in the EU
6.3.1 The EU is the Leading Destination for Pharma Contract Manufacturing
6.3.2 Regulatory Aspects to Pharma Manufacturing in the EU
6.3.2.1 The European Commission Amends Annex 16
6.3.2.2 The Falsified Medicine Directive: Controlling API Imports
6.3.3 Biopharma Manufacturing Demand Will Rise to 2025
6.3.4 The EU Contract Manufacturing Submarket Forecast 2015-2025
6.3.5 Germany: The Leading EU Destination for API and FDF Manufacturing
6.3.5.1 Demand for Contract Manufacturing in Germany: Revenue Forecast 2015-2025
6.3.6 CMOs Account for a Third of Manufacturing Sites in France
6.3.6.1 French Pharma Contract Manufacturing Submarket Forecast 2015-2025
6.3.7 Italy: Strong API Manufacturing Traditions
6.3.7.1 Revenue Forecast for the Italian Pharma Contract Manufacturing Submarket 2015-2025
6.3.8 Spain: How Will Demand for Manufacturing Services Grow to 2025?
6.3.9 The UK: Pharma Contract Manufacturing Submarket Forecast 2015-2025
6.4 Pharma Contract Manufacturing in Japan 2015-2025
6.4.1 Pharma Manufacturing Regulations in Japan
6.4.1.1 The Pharmaceutical Affairs Law
6.4.2 Greater API Outsourcing to Drive Japanese Submarket Growth to 2025

7. Pharma Contract Manufacturing: Leading Emerging National Markets 2015-2025
7.1 Pharma Contract Manufacturing in Developing Countries
7.1.1 Outsourcing to Emerging National Markets from Developed Markets
7.1.1.1 Demand for Services in India and China
7.1.2 Domestic Demand for Pharma Contract Manufacturing Services
7.1.3 Pharma Contract Manufacturing: Leading Emerging National Market Forecasts 2015-2025
7.2 Chinese Demand for Pharma Contract Manufacturing Services 2015-2025
7.2.1 Improved Manufacturing Regulations in China
7.2.1.1 New Regulations for Excipients and Guidance for API Manufacturing 2012-2013
7.2.1.2 What Are the Consequences to Stricter Manufacturing Regulations in China?
7.2.2 Chinese CMOs Are Investing in Biopharma Manufacturing
7.2.3 China Pharma Contract Manufacturing Submarket Forecast 2015-2025
7.3 India: CMOs with Growing Formulation Experience
7.3.1 Regulatory Outlook for Indian Pharma Manufacturing
7.3.1.1 Ensuring Compliance with New Rules in the EU
7.3.2 Domestic Manufacturing Dominates the Indian Pharma Market
7.3.3 Demand for Contract Manufacturing in India: Submarket Forecast 2015-2025
7.4 Brazil: Contract Manufacturing Outlook 2013-2025
7.4.1 Pharma Manufacturing Regulations in Brazil
7.4.1.1 New Guidelines and Regulations Proposed 2012-2013
7.4.2 Brazil Imports Most of its APIs
7.4.3 Brazil: Pharma Contract Manufacturing Submarket Forecast 2015-2025
7.5 The Russian Pharma Contract Manufacturing Submarket 2015-2025
7.5.1 Pharma Manufacturing Regulations in Russia
7.5.1.1 Compliance with GMP in Russia
7.5.2 How Will Demand for Contract Manufacturing Grow in Russia 2015-2025?
7.6 South Korea
7.6.1 South Korea: Strict GMP Regulations
7.6.2 South Korea: Pharma Contract Manufacturing Submarket Forecast 2015-2025

8. Pharma Contract Manufacturing Industry Trends: CMO Perspective 2015-2025
8.1 Pharma Contract Manufacturing Market: Strengths and Weaknesses for CMOs 2013-2014
8.2 Pharma Contract Manufacturing Market: Opportunities and Threats for CMOs 2015-2025
8.3 Pharma Contract Manufacturing Market: STEP Analysis 2015-2025
8.3.1 Social Factors
8.3.2 New Technologies Will Drive Market Growth to 2025
8.3.2.1 Single-Use Technologies in Biopharma Manufacturing
8.3.2.2 Green Technology in Contract Manufacturing
8.3.2.3 Drug Delivery Trends and CMOs
8.3.2.4 Biologics Are Causing Increased Demand for Lyophilisation
8.3.2.5 Improving Solubility and Stability for Small Molecules
8.3.2.6 Spray Drying as an Alternative to Lyophilisation
8.3.2.7 Hot-Melt Extrusion
8.3.3 Economic Pressures
8.3.3.1 Developed-Market CMOs Face Competition from Emerging Markets
8.3.4 Political Issues
8.3.4.1 How Will Regulatory Developments Affect CMOs?
8.4 Trends in Drug Development Affecting CMOs to 2025
8.4.1 Orphan Drug Development: Smaller Manufacturing Capacities
8.4.2 Complex Biologics: Interest in ADCs is Rising
8.4.3 How Will Biosimilar Market Growth Affect CMOs?
8.4.4 The Future of Small Molecule Outsourcing
8.5 How Will CMOs Expand in the Coming 10 Years?
8.5.1 CMO Consolidation Will Increase
8.5.2 There Will be More Manufacturing Facilities Available for Acquisition
8.6 Developments in the Manufacturing Process 2015-2025
8.6.1 Quality by Design (QbD)
8.6.2 A Move Towards Continuous Manufacturing?

9. Pharma Contract Manufacturing Industry Trends: Client Perspective 2015-2025
9.1 Pharma Contract Manufacturing: Client Perspective Industry Strengths and Weaknesses 2013-2014
9.2 Pharma Contract Manufacturing: Client Perspective Industry Opportunities and Threats 2015-2025
9.3 Important Aspects of the Outsourcing Decision
9.3.1 What Factors Will Influence CMO Selection?
9.3.2 CMO-Pharma Partnering Models
9.3.3 Strategic Partnering
9.3.4 Selecting a Local CMO vs. Offshoring
9.3.5 CMOs in Emerging Markets
9.3.6 Communication
9.3.7 Ensuring Protection in Intellectual Property and Tech Transfer
9.3.8 Regulatory Compliance is a Key Deciding Factor for Pharma Clients
9.3.8.1 Regulatory Bodies and Outsourcing
9.3.8.2 Quality Agreement
9.3.8.3 Global Harmonisation Will Improve Compliance
9.4 Trends in Outsourcing Partnerships 2015-2025
9.4.1 Big Pharma and Outsourced Manufacturing
9.4.2 Small and Virtual Pharma Companies
9.4.3 How Will Biotech Funding Affect the Pharma Contract Manufacturing Industry to 2025?

10. Research Interviews from Our Industry Survey
10.1 Dr Cynthia Wooge, Global Strategic Marketing Manager, SAFC
10.1.1 SAFC
10.1.2 Are ADCs Limited to Oncology?
10.1.3 The Challenges of ADCs Manufacturing
10.1.4 What Solution Does SAFC Offer for ADCs Manufacturing?
10.1.5 Advancement in Conjugation Technology
10.2 Mr. Peter Soelkner, Managing Director of Vetter Pharma International GmbH
10.2.1 Vetter
10.2.2 Singapore, a Global Biomedical Sciences Hub
10.2.3 Market Outlook for APAC Region
10.2.4 Challenges to Be Addressed in the APAC Region

11. Conclusions of the Study
11.1 The World Pharma Contract Manufacturing Market
11.2 Outlook for the Market to 2025
11.2.1 Rising Demand for High Value Services 2015-2025
11.2.2 Demand Will be Highest Among Developed Market Clients
11.3 Which New Technologies Will Stimulate Demand to 2025?


List of Tables
Table 1.1 Pharmaceutical Contract Manufacturing Market: Overall Market and Revenue Forecasts by Sector ($bn), 2015-2025
Table 1.2 Currency Exchange Rates
Table 3.1 Pharma Contract Manufacturing Market Revenue ($bn), 2012-2013
Table 3.2 Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Sector, 2013
Table 3.3 Pharma Contract Manufacturing Market: Overall Market and Revenue Forecasts by Sector ($bn), 2015-2025
Table 3.4 Pharma Contract Manufacturing Market: Submarket Shares (%), 2014-2025
Table 3.5 Other Services Submarket Forecast ($bn), 2015-2025
Table 3.6 Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Development Stage, 2013
Table 3.7 Clinical Manufacturing Submarket Forecast ($bn), 2015-2025
Table 3.8 Commercial Manufacturing Submarket Forecast ($bn), 2015-2025
Table 3.9 Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Top Company, 2013
Table 3.10 Catalent: Revenue ($bn), 2009-2014
Table 3.11 Lonza Custom Manufacturing: Revenue ($bn), 2009-2013
Table 3.12 DSM Pharmaceutical Products: Revenue ($bn), 2009-2013
Table 3.13 Teva API: Revenue ($bn), 2009-2013
Table 3.14 Patheon: Revenue ($bn), 2009-2013
Table 3.15 Boehringer Ingelheim BioXcellence: Revenue ($bn), 2011-2013
Table 3.16 Famar: Revenue ($bn), 2009-2013
Table 4.1 Contract API Manufacturing Submarket Revenue ($bn), 2012-2013
Table 4.2 Contract API Manufacturing Submarket: Revenue ($bn) and Submarket Share (%) by Sector, 2013
Table 4.3 Contract API Manufacturing Submarket: Overall Submarket and Revenue Forecasts by Sector ($bn), 2015-2025
Table 4.4 Contract API Manufacturing Submarket: Submarket Shares (%), 2014-2025
Table 4.5 Contract API Manufacturing Submarket: Drivers and Restraints, 2015-2025
Table 4.6 Contract Generic API Manufacturing Submarket Forecast ($bn), 2015-2025
Table 4.7 Contract Generic API Manufacturing Submarket: Drivers and Restraints, 2015-2025
Table 4.8 Contract HPAPI Manufacturing Submarket Forecast ($bn), 2015-2025
Table 4.9 Contract HPAPI Manufacturing Submarket: Drivers and Restraints, 2015-2025
Table 5.1 Contract FDF Manufacturing Submarket Revenue ($bn), 2012-2013
Table 5.2 Contract FDF Manufacturing Submarket: Revenue ($bn) and Submarket Share (%) by Sector, 2013
Table 5.3 Contract FDF Manufacturing Submarket: Overall Submarket and Revenue Forecasts by Sector ($bn), 2015-2025
Table 5.4 Contract FDF Manufacturing Submarket: Segment Shares (%), 2014-2025
Table 5.5 Contract FDF Manufacturing Submarket: Drivers and Restraints, 2015-2025
Table 5.6 Contract Solid Dosage Manufacturing Submarket Forecast ($bn), 2015-2025
Table 5.7 Contract Solid Dosage Manufacturing Submarket: Drivers and Restraints, 2015-2025
Table 5.8 Contract Injectable Dosage Manufacturing Submarket Forecast ($bn), 2015-2025
Table 5.9 Contract Injectable Dosage Manufacturing Submarket: Drivers and Restraints, 2015-2025
Table 5.10 ADCs in Phase II and III Development, 2013
Table 5.11 Selected CMOs Investing in ADC Manufacturing Capacity, 2014
Table 6.1 Pharma Contract Manufacturing Market: Revenues ($bn) and Market Shares (%) by Region, 2013
Table 6.2 Pharma Contract Manufacturing Market: Regional Revenue Forecasts ($bn), 2015-2025
Table 6.3 Pharma Contract Manufacturing Market: Developed Market Submarket Shares (%), 2014-2018
Table 6.3 (Cont’d) Pharma Contract Manufacturing Market: Developed Market Submarket Shares (%), 2019-2025
Table 6.4 GDUFA: Annual Fees for Domestic and Foreign Manufacturing Sites, 2014-2015
Table 6.5 US Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 6.6 EU Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Leading Country, 2013
Table 6.7 Catalent: Revenue ($bn) and Assets (%) by Region, 2013
Table 6.8 EU5 Pharma Contract Manufacturing Market: National Submarket Forecasts ($bn), 2015-2025
Table 6.8 (Cont’d) EU Pharma Contract Manufacturing Market: National Submarket Forecasts ($bn), 2015-2025
Table 6.9 German Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 6.10 Selected French Manufacturing Site Acquisitions, 2009-2013
Table 6.11 French Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 6.12 Italian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 6.13 Spanish Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 6.14 UK Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 6.15 Japanese Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 7.1 Pharma Contract Manufacturing Market: Emerging Market Revenue ($bn) and Market Share (%) by Top Country, 2013
Table 7.2 Pharma Contract Manufacturing Market: Leading Emerging Market Submarket Forecasts ($bn), 2015-2025
Table 7.3 Pharma Contract Manufacturing Market: Emerging Market Submarket Shares (%), 2014-2025
Table 7.3 (Cont’d) Pharma Contract Manufacturing Market: Emerging Market Submarket Shares (%), 2014-2025
Table 7.4 Chinese Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 7.5 Indian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 7.6 Brazilian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 7.7 Russian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 7.8 South Korean Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Table 8.1 Pharma Contract Manufacturing Market Strengths and Weaknesses: CMO Perspective, 2015-2025
Table 8.2 Pharma Contract Manufacturing Market Opportunities and Threats: CMO Perspective, 2015-2025
Table 8.3 Pharma Contract Manufacturing Market: STEP Analysis, 2015-2025
Table 8.4 Selected Lyophilisation Service Providers, 2014
Table 8.5 Lyophilisation vs. Spray Drying: A Comparison
Table 8.6 Selected Orphan Drug Prices, 2013
Table 8.7 Biological Manufacturing Expansion, 2011-2013
Table 8.8 Selected CMOs Growing Faster than the Market, 2007-2012
Table 8.9 Regional Market Expansion, 2010-2013
Table 9.1 Pharma Contract Manufacturing Market Strengths and Weaknesses: Client Perspective, 2015-2025
Table 9.2 Pharma Contract Manufacturing Market Opportunities and Threats: Client Perspective, 2015-2025
Table 9.3 Benefits and Risks to Outsourcing Pharma Manufacturing, 2015
Table 9.4 ICH Guidelines: Key Facts and Adoption, 2000-2012
Table 11.1 Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Sector, 2013, 2019 and 2025
Table 11.2 Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Region, 2013, 2019 and 2025


List of Figures
Figure 2.1 Selected Services Offered by CMOs, 2015
Figure 2.2 Major Trends Affecting Pharma Contract Manufacturing Revenue Growth, 2015-2025
Figure 3.1 Pharma Contract Manufacturing Market Revenue ($bn), 2012-2013
Figure 3.2 Pharma Contract Manufacturing: Market Share (%) by Sector, 2013
Figure 3.3 Pharma Contract Manufacturing Market Forecast ($bn), 2015-2025
Figure 3.4 Pharma Contract Manufacturing Market: Submarket Shares (%), 2019
Figure 3.5 Pharma Contract Manufacturing Market: Submarket Shares (%), 2025
Figure 3.6 Pharma Contract Manufacturing Market: Drivers, 2015-2025
Figure 3.7 Pharma Contract Manufacturing Market: Restraints, 2015-2025
Figure 3.8 Other Services Submarket Forecast ($bn), 2015-2025
Figure 3.9 Pharma Contract Manufacturing: Market Share (%) by Developmental Stage, 2013
Figure 3.10 Clinical Manufacturing Submarket Forecast ($bn), 2015-2025
Figure 3.11 Commercial Manufacturing Submarket Forecast ($bn), 2015-2025
Figure 3.12 Pharma Contract Manufacturing: Market Share (%) by Top Company, 2013
Figure 3.13 Catalent: Revenue ($bn), 2009-2014
Figure 3.14 Lonza Custom Manufacturing: Revenue ($bn), 2009-2013
Figure 3.15 DSM Pharmaceutical Products: Revenue ($bn), 2009-2013
Figure 3.16 Teva API: Revenue ($bn), 2009-2013
Figure 3.17 Patheon: Revenue ($bn), 2009-2013
Figure 3.18 Boehringer Ingelheim BioXcellence: Revenue ($bn), 2011-2013
Figure 3.19 Famar: Revenue ($bn), 2009-2013
Figure 4.1 Contract API Manufacturing Submarket Revenue ($bn), 2012-2013
Figure 4.2 Contract API Manufacturing Submarket: Submarket Share (%) by Sector, 2013
Figure 4.3 Contract API Manufacturing Submarket Forecast ($bn), 2015-2025
Figure 4.4 Contract API Manufacturing Submarket: Submarket Shares (%), 2019
Figure 4.5 Contract API Manufacturing Submarket: Submarket Shares (%), 2025
Figure 4.6 Contract Generic API Manufacturing Submarket Forecast ($bn), 2015-2025
Figure 4.7 Contract HPAPI Manufacturing Submarket Forecast ($bn), 2015-2025
Figure 5.1 Contract FDF Manufacturing Submarket Revenue ($bn), 2012-2013
Figure 5.2 Contract FDF Manufacturing Submarket: Submarket Share (%) by Sector, 2013
Figure 5.3 Contract FDF Manufacturing Submarket Forecast ($bn), 2015-2025
Figure 5.4 Contract FDF Manufacturing Submarket: Submarket Shares (%), 2019
Figure 5.5 Contract FDF Manufacturing Submarket: Submarket Shares (%), 2025
Figure 5.6 Contract Solid Dosage Manufacturing Submarket Forecast ($bn), 2015-2025
Figure 5.7 Contract Injectable Dosage Manufacturing Submarket Forecast ($bn), 2015-2025
Figure 6.1 Pharma Contract Manufacturing Market: Share (%) by Region, 2013
Figure 6.2 Pharma Contract Manufacturing Market: Share (%) by Region, 2019
Figure 6.3 Pharma Contract Manufacturing Market: Share (%) by Region, 2025
Figure 6.4 US Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 6.5 EU5 Pharma Contract Manufacturing Market: Share (%) by Country, 2013
Figure 6.6 EU5 Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 6.7 German Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 6.8 French Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 6.9 Italian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 6.10 Spanish Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 6.11 UK Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 6.12 Japanese Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 7.1 Pharma Contract Manufacturing Market: Emerging Market Share (%) by Top Country, 2013
Figure 7.2 Pharma Contract Manufacturing Market: Emerging Market Share (%) by Top Country, 2013, 2019 and 2025
Figure 7.3 Chinese Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 7.4 Indian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 7.5 Brazilian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 7.6 Russian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 7.7 South Korean Pharma Contract Manufacturing: Submarket Forecast ($bn), 2015-2025
Figure 9.1 Overview of ICH Manufacturing Guidelines, 2013
Figure 11.1 Pharma Contract Manufacturing Market: Revenue ($bn) by Sector, 2013, 2019 and 2025
Figure 11.2 Pharma Contract Manufacturing Market: Revenue ($bn) by Region, 2013, 2019 and 2025

Companies Listed

AbbVie
Actavis
Aegerion Pharmaceuticals
Aenova Group
Aesica Pharma
Agência Nacional de Vigilância Sanitária (ANVISA)
Alexion Pharmaceuticals
Almac Group
Althea Technologies
AMRI
Aneona Group
Asociación Española de Fabricantes de Productos de Química Fina (AFAQUIM)
Aspen Pharmacare
Associação Brasileira da Indústria Farmoquímica e de Insumos Farmacêuticos (ABIQUIFI)
Association of British Pharmaceutical Industry (ABPI)
AstraZeneca
Banner Pharmacaps
Barring Private Equity Asia
Bausch & Lomb
Bayer
Ben Venue Laboratories
Bend Research
Biogen Idec
BioIndustry Association (BIA)
Biotest
Blackstone Group
Boehringer Ingelheim
Boehringer Ingelheim BioXcellence
Bristol-Myers Squibb Company
Bushu Pharmaceuticals
Cambrex
Cambridge Major Laboratories
Carbogen Amcis
Catalent Pharma Solutions
Cedarburg Hauser
Cell Therapy Catapult
Celladon Corporation
Celldex
Celltrion
Cenexi
Central Drugs Standard Control Organization (CDSCO)
Chemisch-Pharmazeutisches Laboratorium Ravensburg
Chemtrix
China FDA (CFDA)
Cipla
Cook Pharmica
CTC Bio
Daito Pharmaceutical
Delpharm
Department of Health and Family Welfare
Development and Reform Commission (NDRC)
Dishman Pharmaceuticals
DPx Holdings B.V.
Dr. Reddy’s Laboratories
Eisai
Eli Lilly
Esteve Quimica
European Commission
European Medicines Agency (EMA)
Euticals
Evonik Degussa
Famar
Fareva
Food and Drug Administration (US FDA)
FUJIFILM Diosynth Biotechnologies,
Gallus Biopharamceutical, LLC.
G-CON
GEA Pharma-Systems
Genentech
GlaxoSmithKline (GSK)
Granules India
Haupt Pharma
Hexal
Hospira
Hospira One2One
Immunogen
Immunomedics
Indian Drug Manufacturer’s Association (IDMA)
Indian Pharmaceutical Alliance
Innovent Biologics
International Society of Pharmaceutical Engineering (IPSE)
Janssen
JK Pharmaceutical
Knowledge Transfer Network (KTN)
Korea Food and Drug Administration (KFDA)
Korea Pharmaceutical Manufacturer’s Association (KPMA)
Lonza
Lupin
Marinopoulos Group
Matrix Laboratories
Medice
Medichem
Medicines and Healthcare Products Regulatory Agency (MHRA)
Medicines Manufacturing Industry Partnership (MMIP)
Merck & Co.
Micron Technologies
Millenium
Ministry of Health (MOH)
Ministry of Health, Labor and Welfare (MHLW)
Ministry of Industry and Information Technology (MIIT)
Mitsui & Co.
Mylan
NPS Pharmaceuticals
Nycomed
Orchid Chemicals & Pharmaceuticals
Oxford Biomedica
Patheon
Pfizer
Pharmaceutical and Medical Devices Agency (PMDA)
Pharmacyclics
Piramal Pharma Solutions
Progenics
Quintiles
Recepta Biopharma
Recipharm
Redwood Bioscience
Rentschler Biotechnologie
Roche
ROVI
Royal DSM
SAFC
SafeBridge
Samsung BioLogics
Sandoz
Sanofi
Seattle Genetics
SELLAS Life Sciences Group
Shandong Xinhua
ShangPharma
Shire
Siegfried
Sigmar Italia
Sinochem
SMS Pharmaceuticals
Stada
Stem CentRx
Stevenage Bioscience Catalyst
Takeda
Teva API
Thermo Fisher Scientific
UMN Pharma
UNIGEN
Valeant Pharmaceuticals
Valerion Therapeutics, LLC.
Vetter Pharma-Fertigung GmbH
Vivante GMP Solutions
West Pharmaceutical Services
World Health Organization (WHO)
WuXi PharmaTech
Zhangjiang Biotech & Pharmaceutical Base Company
Zhejiang Jiang Yuan Tang Biotechnology

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close